Single-Institution Experience in the Management of Patients with Clinical Stage I and II Cutaneous Melanoma: Results of Sentinel Lymph Node Biopsy in 240 Cases

Abstract

The status of the SLN provides accurate staging for identifying patients who may benefit from further therapy and is the most important prognostic factor of relapse-free survival.

Prognostic Usefulness of Sentinel Lymph Node Biopsy for Patients Who Have Clinically Node Negative, Localized, Primary Invasive Cutaneous Melanoma

“…The proportion of thin tumors ranged from a low of 1.1% 24 to a high of 30.4%. 26 The proportion of thick tumors ranged from a low of 5.3% 25 to a high of 30.3%. 24 In 3 reports, 34,36,39 distribution of tumor thickness was not provided.…”

“…eTable 2 presents 19 case series 16,[22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] of patients with any tumor thickness. The risk of CM-related death ranged from 0% to 47.8% for cases with a positive SLNB result and 0% to 11.9% for cases with a negative SLNB result.…”

Sentinel node biopsy in melanoma: a single-centre experience with 216 consecutive patients

“…6,7 The detection rate of metastases in nonsentinel nodes (5%) is even lower in our cohort than described elsewhere, with a wide range of 7Á4-34% in the international literature, although it is noteworthy that not all authors report these results. 8,9 In our cohort there was a relatively high rate of both thin melanomas and detection of lymph node metastases by routinely performed ultrasound prior to surgery followed by lymphadenectomy, without prior SNB; this might explain the low predictive value of a positive sentinel node.…”

Evaluation of Sentinel Lymph Node Status and its Association with Clinicopathological Factors in Patients with Cutaneous Melanoma: A Retrospective Study

“…Pathologic examination of the SLNs was performed at the hospital using standard methods that have already been reported (39)(40)(41)(42). The patients who met the following inclusion criteria, were selected for the statistical analysis; the presence of clinical stage I or II, absence of distant metastases con rmed generally by physical examination, chest radiology and the abdominal cavity ultrasonography, and Breslow thickness equal to or above 0.75 mm.…”